In vitro activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in Northern Taiwan

Chang Gung Medical Journal

Volumn 34, Issue 6, 2011, Pages 580-589

  Lee, Sai Cheong ^a   Huang, Shie Shian ^a   See, Lai Chu ^b   Tsai, Ming Han ^a   Shieh, Wen Ben ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

In vitro activities; Nine current antibiotics; Nosocomial isolates

Indexed keywords

CEFPIROME; COLISTIN; DAPTOMYCIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; OXACILLIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER HEMOLYTICUS; AEROMONADACEAE; AEROMONAS HYDROPHILA; ALCALIGENES FAECALIS; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CHRYSEOBACTERIUM MENINGOSEPTICUM; CITROBACTER AMALONATICUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORYNEBACTERIUM; CORYNEBACTERIUM JEIKEIUM; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; OXACILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PANTOEA AGGLOMERANS; PROTEUS MIRABILIS; PROVIDENCIA ALCALIFACIENS; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERITIDIS; SERRATIA LIQUEFACIENS; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS BOVIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; TAIWAN;

ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84555196983     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Cunha BA. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med Clin North Am 2001;85:79-114.
2. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother 2004;16:437-41.
3. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002;49:999-1005.
4. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005;118:29S-38S.
5. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003;22:551-6.
6. Jones RN, Croco MA. Kugler C, Pfaller MA, Beach L. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 2000;37:115-25.
7. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin Infect Dis 2000;31(Suppl 2):S16-23.
8. Lyytikainen O, Rautio M, Carlson P, Anttila VJ, Vuento R, Sarkkinen H, Kostiala A, Vaisanen ML, Kanervo A, Ruutu P. Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother 2004;53:631-4.
9. MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005;11:1197-204.
10. Mochizuki T, Okamoto N, Yagishita T, Takuhiro K, Mashiko K, Ogawa FO, Tosaka N, Kurokawa A, Yamamoto Y. Analysis of antimicrobial drug resistance of Staphylococcus aureus strains by WHONET 5: microbiology laboratory database software. J Nippon Med Sch 2004;71:345-51.
11. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26: 43-9.
12. Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, Chang SC, Ho SW, Lee CY, Hsieh WC, Luh KT. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 2002;8:63-8.
13. Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, Wang JH, Lin CF, Shyr JM, Ko WC, Wu JJ, Liu YC, Huang WK, Teng LJ, Liu CY. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 2009;28:215-20.
14. Huang SC, Lee SC, Lee N, See LC, Tsai MH, Shieh WB. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem and piperacillin/tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. J Microbiol Immunol Infect 2007;40:134-40.
15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1998;16:128-40.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. M7-A7, January, 2006.
17. Liu JW, Jang TN, Cheng YJ, Hsu GJ, Sun W, Lu CT, Hsueh PR. Comparison of the Etest and broth microdilution method for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan. Int J Antimicrob Agents 2010;35:200-1.
18. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007;45:227-30.
19. Galani I, Kontopidou F, Souli M, Rekatsina PD, Koratzanis E, Deliolanis J, Giamarellou H. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008;31:434-9.
20. Wikler MA, Cockerill FR, Bush K, Dudley MN, Eliopoulos GM. Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement. Clinical and Laboratory Standards Institute 2009;M100-S19.
21. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007;45:2173-9.
22. Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson RJ, Kilburn L, Bast DJ, Azavedo J, Low DE. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
23. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
24. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Karlowsky JA. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 2003;47:3089-98.
25. Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 beta-lactamaseproducing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol 2004;42:3978-84.
26. West MB, Boulanger R, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, Fowler C, Morgan N, Kahn JB. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485-506.
27. Kucukates E. Antimicrobial resistance among Gram-negative bacteria isolated from intensive care units in a Cardiology Institute in Istanbul, Turkey. Jpn J Infect Dis 2005;58:228-31.
28. Yamasaki K, Komatsu M, Shimakawa K, Satoh K, Nishio H, Sueyoshi N, Toyokawa M, Sakamoto M, Higuchi T, Wada Y, Kofuku T, Orita T, Yamashita T, Kinoshita S, Aihara M. In vitro activity of beta-lactams and quinolones against AmpC beta-lactamase-producing Escherichia coli. J Infect Chemother 2005;11:9-13.
29. Steward CD, Wallace D, Hubert K, Lawton R, Fridkin SK, Gaynes RP, McGowan JE, Tenover FC. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis 2000;38:59-67.